- Home
- HSCS vs SONN Comparison
HSCS vs SONN Comparison
Compare HSCS & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- SONN
- Stock Information
- Founded
- HSCS 2007
- SONN N/A
- Country
- HSCS United States
- SONN United States
- Employees
- HSCS N/A
- SONN N/A
- Industry
- HSCS Medical Specialities
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- SONN Health Care
- Exchange
- HSCS Nasdaq
- SONN Nasdaq
- Market Cap
- HSCS 2.8M
- SONN 2.5M
- IPO Year
- HSCS 2022
- SONN N/A
- Fundamental
- Price
- HSCS $3.17
- SONN $1.40
- Analyst Decision
- HSCS Strong Buy
- SONN Strong Buy
- Analyst Count
- HSCS 2
- SONN 2
- Target Price
- HSCS $13.50
- SONN $38.00
- AVG Volume (30 Days)
- HSCS 16.4K
- SONN 70.0K
- Earning Date
- HSCS 03-25-2025
- SONN 02-13-2025
- Dividend Yield
- HSCS N/A
- SONN N/A
- EPS Growth
- HSCS N/A
- SONN N/A
- EPS
- HSCS N/A
- SONN N/A
- Revenue
- HSCS $14,700.00
- SONN $1,000,000.00
- Revenue This Year
- HSCS $174.19
- SONN N/A
- Revenue Next Year
- HSCS $4,100.00
- SONN N/A
- P/E Ratio
- HSCS N/A
- SONN N/A
- Revenue Growth
- HSCS 151.28
- SONN 674.14
- 52 Week Low
- HSCS $2.36
- SONN $1.30
- 52 Week High
- HSCS $13.50
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- HSCS 35.81
- SONN 37.25
- Support Level
- HSCS $2.62
- SONN $1.30
- Resistance Level
- HSCS $3.09
- SONN $1.52
- Average True Range (ATR)
- HSCS 0.32
- SONN 0.10
- MACD
- HSCS -0.09
- SONN -0.00
- Stochastic Oscillator
- HSCS 20.55
- SONN 33.33
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.